UNSPSC 51282123: Sulopenem

This classification denotes a beta-lactam antibiotic with the molecular formula C12H15NO5S3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier XX514BJ1XW, chemically known as 4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-7-oxo-3-((tetrahydro-3-thienyl)thio)-, s-oxide, (5r-(3(1r*,3s*),5alpha,6alpha(r*)))- but more generally known as sulopenem, which bears U.S. National Institutes of Health Compound Identifier 71341.

UNSPSC 51282123 Sulopenem, a Commodity code, shows no recent state and local procurement activity aligned with its nominal scope. The two opportunities tagged under this code in the recent activity block involve antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) and opioid-reversal agents (Naloxone), neither of which are sulopenem—a beta-lactam antibiotic in a distinct pharmacological class. State and local health departments and county health authorities do source pharmaceutical products through cooperative purchasing vehicles and piggyback arrangements, including via MMCAP Infuse and similar consortia, but the recorded opportunities under this code do not reflect actual sulopenem procurement.

The Illinois Department of Public Health awarded a pharmaceutical piggyback contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 for Doxycycline and Ciprofloxacin ($2,999,999.11 over three years), and Seminole County, Florida released an IFB in June 2026 for annual supplies of Naloxone (1,900 units) and Safe Drug Deactivation Systems (800 units) with quarterly delivery requirements. The code shows activity in Florida and Illinois, but neither solicitation targets sulopenem specifically. Firms pursuing sulopenem sales to state and local health agencies should verify whether opportunities are correctly coded under this commodity or whether sulopenem demand appears under a different UNSPSC classification.